Lungpacer Announces CMS NTAP Approval for AeroPace® System in FY2026 IPPS Final Rule
Exton, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) — Lungpacer Medical Inc., a medical technology company focused on neurostimulation therapies for critically ill patients, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-on Payment (NTAP) status for the AeroPace® System under the Fiscal Year 2026 Inpatient Prospective Payment System (IPPS) Final Rule, effective October 1, 2025.
